Search

Search Constraints

You searched for: Author/Creator Takezako, Naoki

Search Results

1. A comparison of minimal residual disease detection in autografts among ASO‐qPCR, droplet digital PCR, and next‐generation sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation. (22nd December 2017)

2. An evaluation of the Japanese Society on Thrombosis and Hemostasis criteria for disseminated intravascular coagulation as a predictor of prognosis in patients with infection. (6th July 2021)

3. Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan. Issue 3 (3rd April 2017)

4. Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan. Issue 3 (March 2017)

6. Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation. Issue 1 (29th November 2017)

7. Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D‐first study. Issue 9 (September 2015)

8. Eight‐color multiparameter flow cytometry (EuroFlow‐NGF) is as sensitive as next‐generation sequencing in detecting minimal/measurable residual disease in autografts of patients with multiple myeloma. Issue 1 (24th January 2023)

9. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial. Issue 3 (12th August 2022)

10. Gene Expression Profile Signature of Aggressive Waldenström Macroglobulinemia with Chromosome 6q Deletion. (4th October 2018)